Patents Assigned to Senju Pharmaceutical Co., Ltd.
-
Patent number: 8871813Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: April 25, 2014Date of Patent: October 28, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Publication number: 20140243413Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. An embodiment of said liquid preparation does not include any preservative. Said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: ApplicationFiled: May 5, 2014Publication date: August 28, 2014Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shirou SAWA, Shuhei FUJITA, George A. BAKLAYAN, Angeliqueo E. PADILLA
-
Publication number: 20140235721Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shirou SAWA, Shuhei FUJITA
-
Patent number: 8802705Abstract: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: GrantFiled: May 20, 2008Date of Patent: August 12, 2014Assignees: Senju Pharmaceutical Co., Ltd., Nippon Chemiphar Co., Ltd.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Patent number: 8784789Abstract: An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.Type: GrantFiled: July 30, 2003Date of Patent: July 22, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventor: Masayo Higashiyama
-
Patent number: 8754131Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: January 28, 2014Date of Patent: June 17, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Publication number: 20140142183Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shirou SAWA, Shuhei FUJITA
-
Patent number: 8697751Abstract: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2? in a preparation containing prostaglandin F2?. The object was attained by formulating a prostaglandin F2? derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.Type: GrantFiled: August 10, 2011Date of Patent: April 15, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Yusuke Sakai, Akira Ohtori
-
Patent number: 8697746Abstract: A solid dispersion comprising ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester made amorphous in the presence of a water-soluble cellulosic polymer has improved storage stability. The solid dispersion also has improved solubility for an improved bioavailability.Type: GrantFiled: July 13, 2011Date of Patent: April 15, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Andrew Xian Chen, John Fan, Masazumi Yamaguchi
-
Patent number: 8684173Abstract: The present invention provides a before-use mixing container in which it is possible to easily perform a mixing operation for two types of medicinal solutions and it is not until a mixing operation is performed that a medicinal solution is extracted for use from inside a container.Type: GrantFiled: April 1, 2010Date of Patent: April 1, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Tadashi Otsuka, Takashi Fujimoto
-
Patent number: 8669290Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: November 28, 2012Date of Patent: March 11, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Patent number: 8658703Abstract: Addition of polyvinylpyrrolidone and a water-soluble anionic macromolecular compound to an aqueous suspension of a hardly soluble drug allows to provide an aqueous suspension in which aggregation of drug particles, formation of macro crystals from suspended particles and formation of secondary particles from deposited particles are prevented, and adhesion and adsorption to containers made of plastics, e.g., polypropylene or polyethylene, are avoided. As it has a good redispersibility, the aqueous suspension is useful as eye drops, nasal drops, ear drops, injections, oral preparations, liniments and lotions.Type: GrantFiled: June 15, 2009Date of Patent: February 25, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventor: Shirou Sawa
-
Patent number: 8637544Abstract: The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction.Type: GrantFiled: April 18, 2008Date of Patent: January 28, 2014Assignees: Senju Pharmaceutical Co., Ltd., Astellas Pharma Inc.Inventors: Chiho Yabuta, Fumiko Yano, Mitsuyoshi Azuma
-
Patent number: 8518996Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.Type: GrantFiled: September 14, 2012Date of Patent: August 27, 2013Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Tomoko Fujimoto
-
Patent number: 8518412Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.Type: GrantFiled: September 16, 2010Date of Patent: August 27, 2013Assignee: Senju Pharmaceutical Co, Ltd.Inventors: Takeshi Nakajima, Tomoko Nakajima, Mitsuyoshi Azuma
-
Patent number: 8497304Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: January 19, 2012Date of Patent: July 30, 2013Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Patent number: 8450295Abstract: The present invention provides an ophthalmic composition containing xanthan gum, or xanthan gum and an amino acid, which has a superior corneal epithelial disorder-treating effect and a superior corneal epithelial cell-protecting effect.Type: GrantFiled: April 26, 2010Date of Patent: May 28, 2013Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Koji Doi, Hiroshi Aki
-
Publication number: 20130090384Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: ApplicationFiled: November 28, 2012Publication date: April 11, 2013Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventor: SENJU PHARMACEUTICAL CO., LTD.
-
Patent number: 8383130Abstract: The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.Type: GrantFiled: March 19, 2009Date of Patent: February 26, 2013Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Takeshi Nakajima, Mitsuyoshi Azuma
-
Publication number: 20120288482Abstract: The present invention aims to provide a means for effectively and conveniently treating diseases wherein corneal endothelial cells poor in proliferative capacity in vivo are damaged. The present invention provides a therapeutic agent for corneal endothelial dysfunction containing (R)-(+)-N-(1H-pyrrolo [2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide <Y-39983> or a pharmacologically acceptable salt thereof (compound (Ia)) as active ingredient, an agent for promoting adhesion of corneal endothelial cells, containing compound (Ia), a culture medium for corneal endothelial cells, containing the agent for promoting adhesion, an implant for corneal endothelial keratoplasty, containing corneal endothelial cells, scaffold and compound (Ia), and a production method of a corneal endothelial preparation, including a step of cultivating corneal endothelial cells using the culture medium.Type: ApplicationFiled: December 28, 2010Publication date: November 15, 2012Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SENJU PHARMACEUTICAL CO., LTD.Inventors: Hiroaki Takahashi, Yuji Sakamoto, Tetsuo Kida, Takeshi Tarui